This is your moment.
HTS at CRL
Our High Throughput Screening (HTS) department spans 2 key sites (Chesterford Park in the UK & Leiden in the NL). The department is responsible for delivery of both molecular target-based and phenotypic screening campaigns, helping to identify and qualify ‘hits’ for our client projects. Our department is led by industry experts with several years’ experience in the design and execution of Hit identification cascades – with groups and teams covering a range of different skillsets across biochemical and cellular screening techniques.
We have a strong team culture – with regularly sharing best practise and ensuring learning across our different sites to ensure a smooth and consistent client experience from a single joined-up global department.
HTS at Charles River
Our High Throughput Screening (HTS) department spans 2 key sites (Chesterford Park in the UK & Leiden in the NL). The department is responsible for delivery of both molecular target-based and phenotypic screening campaigns, helping to identify and qualify ‘hits’ for our client projects. Our department is led by industry experts with several years’ experience in the design and execution of Hit identification cascades – with groups and teams covering a range of different skillsets across biochemical and cellular screening techniques.
We have a strong team culture – with regularly sharing best practise and ensuring learning across our different sites to ensure a smooth and consistent client experience from a single joined-up global department.
What is HTS?
The short answer: The most exciting area of drug-discovery!... HTS is the place where Biology & Chemistry first meet – working in this domain means that you get to be right at the forefront of the drug-discovery process (developing novel biological assays and identifying those initial putative ‘hit’ molecules which are the starting point of novel therapeutics
The longer answer: CRL considers a project to be ‘HTS’ when many compounds (generally from 10K up to 1MM or beyond) are tested in a single screening activity. Client’s come to us to help them initiate their drug-discovery projects either through screening of our in-house chemical library or their own proprietary library. Our scientists work in close collaboration with our clients’ team to deliver a full hit identification program from inception to qualified and clustered starting points for on-going drug-discovery activities.
We use the below definition to describe HTS:
-
HTS (diversity screening): A screening paradigm that enables coverage of broad chemical diversity in a single activity, with few target prerequisites. Hundreds of thousands of compounds can be screened in each experimental run, to deliver fast, efficient and (most crucially) consistent data.
-
Phenotypic HTS: A diversity screening approach which employs a functional cellular assay as the primary screen (ideally in a disease-relevant cellular model). In this instance it will be unclear as to MOA of the compounds that appear as ‘hits’
Meet the Leadership Team
Roger Clark
Director
Dr. Clark is responsible for leading a global department within the Discovery Sciences division, delivering molecular target-based and phenotypic Hit ID programs for client projects. Dr. Clark is also part of the Discovery Sciences senior management team, overseeing the delivery of the wide-ranging portfolio to ensure client projects are completed on time and within budget.